NTT's core skin permeation technology was developed by Prof. Elka Touitou from the Faculty of Medicine, Hebrew University in Jerusalem, Israel. The Ethosome Delivery System is a patented breakthrough technology for passive non-invasive transdermal and dermal delivery.
The Ethosomal transdermal delivery provides a wide range of drug candidates with the benefit of:
Reduced doses and toxicity compared to oral dosage forms
High patient compliance
Enhancement of a product's life cycle
Significant superiority compared to other drug delivery system
Ethosomal systems were found to be highly superior at delivering drugs through the skin in terms of quantity and depth when compared to liposomes or other existing commercial transdermal/dermal delivery systems. Studies of skin permeation in vitro and in vivo in animals (pharmacokinetic and/or CLSM organ distribution measurements) and human clinical studies showed that Ethosomes are highly superior to other transdermal delivery systems. For more information on the Ethosomes please read the relevant scientific publications on News in our wesbsite.
